AUTHOR=Chen Jiaqi , Yin Min , Yang Chenguang , Wang Kun , Ma Lili , Yu Haiyang , Huang Yue , Liu Feng , Tang Zhaohui 

TITLE=Therapeutic effects and underlying mechanism of poly (L-glutamic acid)-g-methoxy poly (ethylene glycol)/combretastatin A4/BLZ945 nanoparticles on Renca renal carcinoma

JOURNAL=Frontiers in Bioengineering and Biotechnology

VOLUME=12

YEAR=2024

URL=https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2024.1336692

DOI=10.3389/fbioe.2024.1336692

ISSN=2296-4185

ABSTRACT=<p><bold>Introduction:</bold> The prognosis of advanced renal carcinoma is not ideal, necessitating the exploration of novel treatment strategies. Poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/Combretastatin A4 (CA4)/BLZ945 nanoparticles (CB-NPs) possess the dual capability of CA4 (targeting blood vessels to induce tumor necrosis) and BLZ945 (inducing M2 macrophage apoptosis), thereby inhibiting tumor growth.</p><p><bold>Methods:</bold> Here, the therapeutic effects and underlying mechanism was explored by CCK-8 cytotoxicity experiment, transwell cell invasion and migration experiment, H&amp;E, western blot analysis, immunohistochemistry, flow cytometry, and other techniques.</p><p><bold>Results:</bold> These results demonstrated that CB-NPs could inhibit the growth of Renca cells and subcutaneous tumors in mice, with an impressive tumor inhibition rate of 88.0%. Results suggested that CB-NPs can induce necrosis in renal carcinoma cells and tissues, downregulate VEGFA expression, promote renal carcinoma cell apoptosis, and reduce the polarization of M2 macrophages.</p><p><bold>Discussion:</bold> These findings offer innovative perspectives for the treatment of advanced renal carcinoma.</p>